{
  "docId": "019dd923-5ca1-7489-b638-229be117d58e",
  "docSlug": "415e33cb189c4261",
  "documentTitle": "Impact of the US BIOSECURE Act on Biopharmas, Contract Services and Investors",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 2,
  "pageCount": 13,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "appendix_methodology",
  "function": "establish_context",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "The slide provides a methodological overview of the survey sample, including familiarity, geography, sector, and functional role of respondents.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "bar_chart_stacked",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-229be117d58e/2",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-229be117d58e#slide-2",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The US BIOSECURE Act, introduced in Dec. 2023, proposes to prohibit federal contracting with biotechnology providers connected to foreign adversaries.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cc5-5b9907424219",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.64,
        "x": 0.32,
        "y": 0.21
      },
      "kind": "chart",
      "text": "L.E.K. Global Survey on Impact of the US BIOSECURE Act Respondent Mix (June 2024)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6f755fa-835c-42cf-b9db-faad7b6b7be7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Respondent mix: 73",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cc5-5c89423e9147",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.25,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Background\nThe US BIOSECURE Act, introduced in Dec. 2023, proposes to prohibit federal contracting with biotechnology providers connected to foreign adversaries\nIf this goes into effect, it will impact any company that does (or wants to) receive US federal government contracts (i.e., most global pharma companies), and restrict them from partnering with companies of concern, including certain Chinese CROs/CDMOs\nTo understand the sentiments and reactions, L.E.K. conducted a proprietary survey among global life sciences companies\nAt the time of publication of this report, the US BIOSECURE Act had not been passed",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6f3ad70-9a9a-4bb9-a241-35418181cdc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: Total of 73 responses; CRO=contract research organization; CDMO=contract development manufacture organization\nSource: L.E.K. 2024 Global Survey on Impact of US BIOSECURE Act",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e090f1c0-c417-432c-b629-d6d9106be158",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "L.E.K. Consulting conducted a survey on the impact of the US BIOSECURE Act; this June 2024 study engaged respondents across different biopharma and services sectors familiar with the Act",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "719e3a22-808b-4264-94c8-a251cddcc901",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Respondent mix",
      "numberRaw": "73",
      "numberKind": "plain",
      "actionTitle": "L.E.K. Consulting conducted a survey on the impact of the US BIOSECURE Act; this June 2024 study engaged respondents across different biopharma and services sectors familiar with the Act",
      "calloutText": "The US BIOSECURE Act, introduced in Dec. 2023, proposes to prohibit federal contracting with biotechnology providers connected to foreign adversaries.",
      "numberScale": null,
      "numberValue": 73,
      "metricFamily": "survey_sentiment",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 3,
      "from": 1,
      "beatId": "f0590932-f4ae-46a3-a1a6-5e805bd8a9eb",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Situation & Context",
      "beatSlug": "consultants-gambit-situation-context",
      "evidence": "The document provides an overview of the US BIOSECURE Act and its context",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}